Form 4: Cellectar Biosciences COO Acquires Stock Options

Jarrod Longcor, Chief Operating Officer of Cellectar Biosciences, acquired stock options for 500,000 shares on February 14, 2025.

Summary

• Jarrod Longcor, the Chief Operating Officer of Cellectar Biosciences, acquired stock options on February 14, 2025.
• The options grant the right to buy 500,000 shares of common stock at an exercise price of $0.29 per share.
• The options vest over a three-year period, starting with 1/3 vesting on February 14, 2026, and the remainder vesting in 24 equal monthly installments thereafter.
• The options expire on February 14, 2035.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a stock option grant. The sentiment is slightly positive as it indicates alignment of the COO's interests with shareholders.

Positives

• The acquisition of stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen routinely grant stock options to their executives as part of their overall compensation strategy.
• The vesting schedule and exercise price are generally determined based on industry benchmarks and the executive's performance.

Stakeholder Impact

• The stock option grant could potentially incentivize the COO to improve company performance, benefiting shareholders.

Key Dates

Keywords

stock options, Cellectar Biosciences, CLRB, Jarrod Longcor, Chief Operating Officer, Form 4, beneficial ownership